Priority Review for Immunomedics' ADC for TNBC

FDA accepted and granted Priority Review to a BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE